HomeGLTO • NASDAQ
add
Galecto Inc
Previous close
$5.13
Day range
$4.99 - $5.31
Year range
$4.40 - $23.50
Market cap
6.70M USD
Avg Volume
19.06K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 3.84M | -34.42% |
Net income | -3.88M | 52.27% |
Net profit margin | — | — |
Earnings per share | -3.39 | 32.03% |
EBITDA | -3.83M | 32.07% |
Effective tax rate | -0.18% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 19.68M | -55.46% |
Total assets | 23.38M | -53.29% |
Total liabilities | 2.44M | -80.73% |
Total equity | 20.94M | — |
Shares outstanding | 1.32M | — |
Price to book | 0.31 | — |
Return on assets | -37.89% | — |
Return on capital | -43.02% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -3.88M | 52.27% |
Cash from operations | -3.65M | 56.81% |
Cash from investing | 0.00 | -100.00% |
Cash from financing | — | — |
Net change in cash | -3.18M | -2,709.84% |
Free cash flow | -2.08M | 44.50% |
About
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Founded
2011
Headquarters
Website
Employees
13
